A Look at FDA's Proposed Changes to Labeling for Biosimilars and Interchangeable Biosimilars | Foley & Lardner LLP

The labeling of biosimilar products as “interchangeable” may be important in order to gain acceptance and use in the medical community. This article provides important information...

Related Keywords

,Public Health ,Additional Draftq As On Biosimilar Development ,Service Act ,Drug Administration ,Interchangeable Biosimilar Products ,Biosimilar Development ,Changes Included ,Register Notice ,Prescribing Information ,